ARTICLE | Company News

Xencor, Novartis deal

July 11, 2016 7:00 AM UTC

Xencor granted Novartis rights to develop bispecific antibodies using Xencor’s technology, including rights outside the U.S. to Xencor’s XmAb14045 and XmAb13676. The companies will collaborate and share worldwide development costs for the two programs and expect clinical testing to begin this year. Xencor will retain U.S. rights to both compounds and is eligible for low double-digit royalties on ex-U.S. sales for the products.

XmAb14045, a bispecific antibody against CD3 and CD123, is in development to treat acute myelogenous leukemia (AML). XmAb13676, a bispecific antibody against CD20 and CD3, is in development to treat B cell malignancies. ...